House of Lords Business
Show full summary

Lord Hunt of Kings Heath to ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 May (HL147), how the National Institute for Health and Care Excellence (NICE) appraisals of (1) Sacituzumab govitecan (Trodelvy), and (2) Tucatinib (Tukysa) with trastuzumab and capecitabine, were included in the statistic cited as 100 per cent of guidance of new medicines being issued within three months of a licence in 2021/22, where NICE proceeded to appraisal.  HL539

Question HL539: tabled on 25 May 2022 and due for answer by 10 June 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Hunt of Kings Heath to ask Her Majesty's Government, further to the Written Answer by Lord Kamall on 17 May (HL147), how the National Institute for Health and Care Excellence (NICE) appraisals of (1) Sacituzumab govitecan (Trodelvy), and (2) Tucatinib (Tukysa) with trastuzumab and capecitabine, were included in the statistic cited as 100 per cent of guidance of new medicines being issued within three months of a licence in 2021/22, where NICE proceeded to appraisal.  HL539
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Hunt of Kings Heath
Labour
Life peer